JUN 14, 2019 11:18 AM PDT

Attaching a removable lock to an arthritis drug

WRITTEN BY: Nouran Amin

A study published in PLOS Biology suggests that attaching a removable lock to an arthritis drug can increase its effectiveness. The study sheds new light on a drug taken by millions of patients throughout the world.

Learn more about rheumatoid arthritis:

Arthritis drugs, like the monoclonal antibodies infliximab and adalimumab, have been considered breakthrough treatments for their ability to target and inhibit the activity of tumor necrosis factor alpha (TNF-alpha)—which is a key signaling molecule in the autoimmune cascade. However, the use of TNF-alpha blockers has major disadvantages. For one, their use can result in immune suppression. To mitigate the problem, researchers added a removable protein "lock" to the infliximab antibody.

The lock was attached chemically to the active site of the antibody via a protein tag that can be removed by an enzyme called matrix metalloproteinase (MMP).

MMP’s are abundant at the site of rheumatoid arthritis and is implicated in the characteristic tissue breakdown seen in the disease. Therefore, researchers were hopeful that at the site of the disease—and not in inactive in non-arthritic tissues--the high concentrations of MMP would remove the lock and release the active infliximab primarily at the site of disease, while leaving it largely locked and inactive in non-arthritic tissues where MMP levels were lower. Additionally, the researchers hoped that the presence of a lock would alter the shape of the infliximab enough to prevent any anti-infliximab antibodies from developing.

The lock was found to be effective both respects. "The addition of this reversible lock to infliximab has the potential to improve the risk/benefit ratio for patients with rheumatoid arthritis," said lead author of the study, Wen-Wei Lin of Kaohsiung Medical University, Taiwan, "and may serve as a model for improvement of other monoclonal antibody therapies as well. Significant further work will be required before the modified form of the antibody can be tested in a clinical trial in patients”.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 19, 2019
Neuroscience
JUL 19, 2019
Using a popular anti-smoking drug to control brain cells
Researchers develop neuron receptors with the ability to interact with an FDA-approved anti-smoking drug. This technology has the potential to treat pain and seizures in humans....
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Synthetic Oxytocin for Obesity Treatment
According to recent research, the hormone oxytocin reduced the communication in different regions of the brain involved in the cognitive, sensory and emoti...
JUL 19, 2019
Microbiology
JUL 19, 2019
Using Engineered Bacteria to Rapidly Evaluate Therapeutics
Scientists are using genetic tools to engineer bacteria in many ways. These new microbes are able to mimic or sense disease states......
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Self-Inflating Capsule To Tackle Obesity
A team of collaborative researchers have developed a self-inflating weight management capsule used for the treatment of obesity called the EndoPil. The &ls...
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Repurposing Cancer Drug for Treating Brain Aneurysms
Brain aneurysms is a result of a bulging blood vessel due to a weakness in the blood vessel wall. When the blood passes through the weakened vessel walls, ...
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Injectable Hydrogel Recruits Chemotherapeutics to Tumor Site
Targeting tumor cells while avoiding harming healthy tissue remains a growing central challenge in the field of chemotherapeutics. For a while, scientists ...
Loading Comments...